NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics to Participate in Upcoming Investor Conferences

04 Mar 2025 04:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Feb 2025 13:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

28 Jan 2025 13:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

22 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

13 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

19 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

09 Dec 2024 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

02 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

25 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

20 Nov 2024 13:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

21 Oct 2024 13:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

19 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

16 Oct 2024 13:35:41 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

11 Oct 2024 13:00:28 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

09 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

30 Sep 2024 04:00:00 By Nasdaq GlobeNewswire